Ronghan Liu

Dr. Ronghan Liu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HWHui-Hui Wu
Hui-Hui Wu
TMTing-Ting Meng
Ting-Ting Meng
JCJia-Min Chen
Jia-Min Chen
FMFan-Liang Meng
Fan-Liang Meng
SWShu-Ya Wang
Shu-Ya Wang
GSGuohai Su
Guohai Su

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
HDHui Dong
Hui Dong
RLRonghan Liu
Ronghan Liu
KZKe Zou
Ke Zou
ZJZhengxin Jin
Zhengxin Jin
JKJianning Kang
Jianning Kang
BNBin Ning
Bin Ning

24 March 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
XZXiaodi Zhang
Xiaodi Zhang
ZSZhengfang Sun
Zhengfang Sun
YZYing Zhang
Ying Zhang
LPLiuzhu Pan
Liuzhu Pan
WJWei Jiang
Wei Jiang
BNBin Ning
Bin Ning

19 April 2025 in Cell Proliferation
Verified
Journal Article
Open access
ZLZheng Li
Zheng Li
YZYunpeng Zou
Yunpeng Zou
JNJiayao Niu
Jiayao Niu
YZYing Zhang
Ying Zhang
AYAohua Yang
Aohua Yang
RLRonghan Liu
Ronghan Liu
IMPDH2 is a rate-limiting enzyme in guanine nucleotide biosynthesis. It plays diverse roles in various physiological and pathological processes: nucleotide metabolism, inflammation, immune function, ribosomal stress. Structural or regulatory alterations in IMPDH2 are linked to significant health issues, and critical relevance in disease progression. We aim to underscore the potential of IMPDH2 as a promising therapeutic target for clinical applications.

1 January 2019 in JBJS Reviews
Verified
Journal Article
Closed access
YCYuehong Chen
Yuehong Chen
RLRonghan Liu
Ronghan Liu
AHAubryanna Hettinghouse
Aubryanna Hettinghouse
SWShuya Wang
Shuya Wang
GLGang Liu
Gang Liu
CLChuanju Liu
Chuanju Liu
Background: Teriparatide, a 1-34 fragment of parathyroid hormone (PTH) that maintains most of the biological activities of PTH, has been employed since 2002 as an anabolic agent for osteoporotic individuals who are at high risk of fracture. The purpose of the present review is to provide a systematic summary and timely update on treatment with teriparatide for fracture prevention. Methods: Electronic databases, including OVID MEDLINE, OVID Embase, and the Cochrane Library, were searched on February 9, 2018, to identify published systematic reviews and meta-analyses addressing treatment with teriparatide for fracture prevention, and A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2) was used to assess the quality of included studies. Results: Seventeen studies were included. Of the 17 eligible studies, 3 were rated as high quality, 3 were rated as moderate quality, 6 were rated as low quality, and 5 were rated as critically low quality. Teriparatide reduced vertebral and overall nonvertebral fractures in osteoporotic patients regardless of the existence of precipitating conditions, including postmenopausal status, glucocorticoid treatment, and chronic kidney disease, as compared with placebo, but not the site-specific nonvertebral fractures of the wrist and hip. Teriparatide did not more effectively reduce fracture risks when compared with other medications, such as bisphosphonates, selective estrogen receptor modulators, RANKL (receptor activator of nuclear factor kappa-beta ligand) inhibitor, or strontium ranelate. Conclusions: Teriparatide was safe and was not associated with an increased rate of adverse events when compared with other drugs. Teriparatide was effective for the prevention of vertebral and overall nonvertebral fractures in osteoporotic patients but not for the prevention of site-specific nonvertebral fractures at the wrist and hip. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

21 October 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
KLKaiwen Liu
Kaiwen Liu
XZXiaodi Zhang
Xiaodi Zhang
BNBin Ning
Bin Ning
RLRonghan Liu
Ronghan Liu
CWCheng Wang
Cheng Wang
JWJianlu Wei
Jianlu Wei
Cartilage metabolism balance chaos is crucial in the development and progression of osteoarthritis (OA), with chronic low-grade inflammation being the primary factor that leads to chondrocyte metabolic dysregulation. Fexofenadine (FFD) is a widely used commercially available anti-allergy compound, which has been shown to reduce inflammation. The present study finds FFD’s therapeutic effects in primary human ex-vivo cultures and surgically induced murine models. Mechanism study illustrates FFD exhibits chondroprotective effect through anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated inflammation and pro-Transforming Growth Factor Beta (TGFβ)-associated anabolism. Specifically, FFD directly binds to cytosolic phospholipase A2 (cPLA2), down-regulating downstream NF-κB activation, resulting in alleviated catabolism. Notably, Signal Transducer and Activator of Transcription 1 (STAT1) is first identified as FFD’s target by Drug affinity responsive target stability which shows the Gln-314 site is required. FFD blocks STAT1 binds to TGF-β type I receptor, leading to secondary SMAD Family Member 2 (Smad2) phorsphorylation, slightly enhances chondrocyte proliferation and matrix production. Importantly, further study demonstrates FFD directly binds Smad2 by the target proteins fishing technique, remarkably active TGFβ-related biological process. These findings provide new insights into the chondroprotective role of FFD with novel target and downstream pathway, offering promising avenues for the treatment of OA.